Last updated: July 6, 2026
ISOVUE-200 Investment Scenario and Fundamentals Analysis: Patent, Regulatory, Supply, and Competitive Risk for the iopamidol IV Radiocontrast Market
ISOVUE-200 (iopamidol) is a legacy, small-molecule iodinated IV radiocontrast with mature commercialization and broad generic penetration risk. Investment fundamentals hinge on (1) remaining patent/exclusivity headroom (largely extinguished for core iopamidol drug substance), (2) whether line-extensions (concentration, container, osmolality/viscosity handling, manufacturing process) still have enforceable patents, (3) FDA-related product-specific exclusivity and manufacturing/quality reliability, and (4) pricing and contracting dynamics in radiology and hospital group purchasing. This assessment is governed by patent and regulatory realities for iopamidol IV contrast, where the investment skew typically favors distribution scale, supply assurance, and lifecycle management over innovation-led growth.
Core investment lens
- Demand stability: IV iodinated contrast is a routine input for CT angiography, abdominal CT, and interventional radiology. Volume is tied to imaging utilization and payer/provider contracting, not to new clinical paradigms.
- Revenue vulnerability: ISOVUE-200 sits in a space where multiple ANDA products can erode price; gross-to-net compression is common in hospital procurement.
- Switching friction: Hospitals prefer consistent imaging performance and low adverse-event rates, but switching between equivalent iodinated contrasts is feasible when logistics and reimbursement align.
- Risk drivers: FDA compliance and sterility/particulate controls, manufacturing outages, and competitive undercutting typically dominate outcomes.
What is ISOVUE-200 (iopamidol) and how does it fit the IV radiocontrast market?
ISOVUE-200 is an iodinated contrast media product for intravenous administration. Like other nonionic iodinated monomers (e.g., iopamidol, ioversol, iohexol), it is used to increase radiographic contrast in CT and related imaging settings.
Where does it compete?
Primary competitive set in IV iodinated contrast includes:
- Other iopamidol strengths and product presentations
- Competing nonionic iodinated monomers (e.g., ioversol, iohexol, iopromide depending on market geography and formulary status)
- Generic iopamidol IV contrast products to the extent they are approved and supplied
Key market characteristics that shape investment returns
- Procurement-driven economics: Major systems and group purchasing organizations negotiate multi-year contract pricing.
- Safety and tolerability: The market differentiates on viscosity/osmolality handling and perceived safety profile. Clinicians select based on patient risk and workflow.
- Regulatory durability: Once ANDA coverage exists for a given concentration/presentation, pricing pressure tends to persist.
What patents protect ISOVUE-200, and how much enforceable exclusivity remains?
Investment relevance: For legacy iopamidol, the enforceable patent estate (if any) is typically concentrated in:
- Formulation or concentration-specific claims (e.g., 200 mg iodine/mL variants)
- Container or delivery configuration claims
- Manufacturing process claims
- Method-of-use claims (less common for broadly established radiology contrast indication, but still possible for specific protocols)
Practical investor takeaway: Core drug-substance iopamidol is not likely to have meaningful term left in most jurisdictions. The remaining upside usually depends on whether product-specific patents still cover ISOVUE-200’s exact concentration and presentation, and whether they are actively asserted or close to expiration.
How to think about patent headroom in this class
For iodinated contrast media, patent estates often decay faster than investors expect because:
- Generics can be approved when a product’s differences are not protected or are only protected by narrow claims that are hard to read on generic formulations.
- Even where patents exist, litigation outcomes can be settlement-driven, and entry can occur upon the earliest allowed date.
Patent strength metrics investors should track
- Patent list coverage in Orange Book (if applicable) for the specific ISOVUE-200 presentation
- Earliest expiration of:
- Composition/formulation
- Method-of-use
- Process
- Whether any patents have survived final court rulings or have active injunction posture
When does ISOVUE-200 lose exclusivity, and what is the ANDA entry risk window?
Featured-snippet style answer (how this investment decision usually maps to timelines): For legacy IV contrast products like ISOVUE-200, exclusivity risk typically concentrates around the date when any remaining product-specific patents expire and when any Orange Book blocking periods end. Once those constraints lift, ANDA competitors can enter based on the approval pathway timing.
Investment-grade timeline framework
- Patent expiration: earliest date an ANDA can launch if it is not blocked by a still-in-force patent.
- 30-month stay risk (if any Paragraph IV is pending): can delay generic approval and launch, but settlement often defines the actual launch date.
- Launch-to-contract lag: even after approval, formulary replacement and contracting drive realized pricing.
What matters for investors
- The earliest generic launch date for the exact strength and presentation.
- Whether generic versions are authorized supply with stable quality and pricing.
Are there Paragraph IV challenges for ISOVUE-200, and what do they imply for launch timing?
Investment relevance: Paragraph IV challenges can create a predictable entry window based on the 30-month stay and subsequent settlement/entry events.
How to interpret Paragraph IV outcomes
- If multiple ANDAs have Paragraph IV filings, the commercial base can face “batch entry” rather than a single launch, worsening price erosion.
- If the leading challenger settles, the settlement often sets:
- A stipulated launch date
- A design-around position
- Licensing payments and supply terms (if disclosed)
Investor signal
- The number of ANDA filers and whether they target the same specific ISOVUE-200 configuration are more predictive of price pressure than the existence of any single challenge.
(This section requires Orange Book and litigation docket specifics to enumerate actual filings and dates; absent confirmed, citable case data, it cannot be responsibly completed.)
What is the Orange Book status of ISOVUE-200, and which patents are listed for the specific presentation?
Orange Book status determines whether ISOVUE-200 has FDA-listed patents tied to:
- Strength (200 mg iodine/mL)
- Dosage form (injection)
- Container/presentation
Investor use of Orange Book
- Identify the patents that can block ANDA approval/launch.
- Cross-check court-enforced or expired claims.
- Prioritize which patents appear most likely to matter in litigation and settlement leverage.
(This section requires a confirmed Orange Book listing snapshot by NDA/BLA and product presentation. Without a citable listing, it cannot be completed.)
How does ISOVUE-200 compare with other iodinated contrast products (ioversol, iohexol, iopromide) on competitive risk?
Where competition usually lands
- Formulary position: based on contract pricing and perceived image quality.
- Patient-risk use cases: selection may shift toward products with preferred viscosity/osmolality handling.
- Operational compatibility: pharmacy workflow, syringe compatibility, and preparation steps influence switching.
Investment conclusion on competitive position
For ISOVUE-200, the primary economic risk is typically price compression driven by:
- Generic iopamidol entry
- Competitive tender wins by other iodinated contrasts with aggressive pricing
- Supply continuity issues, which can shift volumes temporarily but can be offset by alternative SKUs
What formulations and container presentations are protected for ISOVUE-200?
In legacy contrast media, product protection can be narrow but still commercially material if tied to:
- Specific concentration (200 mg iodine/mL)
- Specific viscosity/osmolality target ranges
- Specific container material and seal configuration
- Specific manufacturing process controls that affect sterility assurance
Investor diligence priorities
- Confirm whether competitors sell “bioequivalent” alternatives that are not design-arounds of a protected formulation.
- Identify whether ISOVUE-200 has multiple presentations where only some are protected, creating an uneven exposure profile.
(This section requires confirmed patent claim coverage by presentation.)
What manufacturing and IP barriers could limit generic competition for ISOVUE-200?
In iodinated contrast media, barriers are often less about chemical synthesis patents and more about:
- Sterility assurance and particulate controls
- Consistency of physicochemical properties
- Scale manufacturing reliability under FDA cGMP
- Supply chain and container filling capacity
How this affects investment fundamentals
- If ISOVUE-200’s supply has been reliable historically, generic erosion can still occur, but the company can retain share through continuity.
- If manufacturing is constrained, the product can maintain pricing even with competition, which can temporarily support margins.
What patent litigation affects ISOVUE-200, and how does it change the risk profile?
Litigation can change fundamentals in three ways:
- Delays entry through court-validated blocking positions
- Triggers settlement-based launch dates
- Clarifies claim scope, enabling design-arounds for entrants
Investor actionability
- Track whether any ISOVUE-200-related disputes include:
- Injunction motions
- Claim constructions that narrow or broaden coverage
- Final appellate outcomes
(This requires verified litigation docket details linked to ISOVUE-200’s exact NDA and Orange Book patents.)
What regulatory and labeling status does ISOVUE-200 have at FDA, and what does it mean for growth?
For mature radiocontrast products:
- FDA approval status usually matters for manufacturing continuity and labeling changes rather than for near-term exclusivity.
- Label changes, safety communications, and manufacturing supplements can impact:
- Distributor and hospital contracting
- Tender documentation requirements
- Pharmacovigilance workflows
Investment implication
A stable regulatory posture supports predictable supply and minimizes tender churn. Frequent label revisions can increase administrative friction, though in legacy products these are usually periodic rather than disruptive.
(This section requires confirmed FDA product record details for ISOVUE-200; cannot be completed without citable data.)
Who are the key companies supplying ISOVUE-200 and competing iodinated contrasts in the US?
In this segment, competition often involves:
- Brand owners and distributors
- Multiple ANDA manufacturers for generic iopamidol products
- Alternative contrast media manufacturers that compete via tenders
What investors should monitor
- Number of approved generic products in the same concentration/presentation
- Whether generics have stable supply continuity
- Wholesale acquisition cost (WAC) trends and contract pricing behavior (to the extent accessible via market benchmarks)
(Company list requires verified product/ANDA supplier mapping.)
How much revenue exposure does ISOVUE-200 face from generic entry and price erosion?
The revenue exposure is typically driven by:
- Share of volumes in high-volume sites (large hospital systems)
- Tender contract structure and replacement cycle
- Presence of therapeutically substitutable alternatives on formularies
- Margin protection through supply reliability and bundling
Investment framework for exposure
- High exposure when:
- Multiple generics can launch post-blocking
- Formularies are permissive across iopamidol and competing iodinated contrasts
- Contract price is the dominant selection factor
- Lower exposure when:
- ISOVUE-200 has long-standing formulary lock-in in major accounts
- Supply constraints favor the brand or authorized supplier
- Clinical workflow supports a stable contrast SKU
(Quantification requires sales history and competitor launch dates.)
What is the investment case for ISOVUE-200: margin durability, growth ceiling, and downside scenarios?
Upside drivers
- Continued high utilization of CT and interventional radiology
- Contracting advantages through reliable supply and logistics
- Potential defensibility of certain presentations if product-specific patents remain
Downside drivers
- Rapid price compression once generics gain entry for the exact strength/presentation
- Lost formulary positions if competitors undercut on tender pricing
- Manufacturing disruptions affecting supply and forcing temporary switching
Most likely scenario in this category
A mature-market outcome where volume is stable but unit economics compress under generic and alternative contrast competition, unless product-specific exclusivity or supply reliability offsets pricing pressure.
Key Takeaways
- ISOVUE-200 is a mature, small-molecule iodinated IV radiocontrast where investment returns are usually driven by contracting and supply reliability, not by innovation-led growth.
- The decisive variable is product-specific patent/exclusivity headroom tied to the exact ISOVUE-200 concentration and presentation, and whether any remaining patents are listed and enforceable.
- Generic entry risk is high once blocking patents expire and any Paragraph IV/settlement events clear.
- In this therapeutic class, operational and regulatory execution (cGMP compliance, sterility and particulate control) can be as financially important as IP.
FAQs
- How do hospital tender cycles affect ISOVUE-200 pricing after generic launches?
- What are the most common patent claim types that can still protect legacy iodinated contrast products like iopamidol?
- Do method-of-use patents meaningfully delay ANDA entry for IV radiocontrast products?
- How does supply continuity influence formulary switching in iodinated contrast media?
- What competitive signals best predict price erosion for ISOVUE-200 in the US market?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. (n.d.). Drugs@FDA. U.S. Food and Drug Administration.
- U.S. Patent and Trademark Office. (n.d.). Patent Public Search. United States Patent and Trademark Office.
